Legal Uncertainty and Competitive Pressures Lead to Hold Rating for Humana
Humana (HUM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joanna Gajuk from Bank of ...
BioPharma Dive2d
J&J joins Pfizer in detailing impact of Part D redesign
The pharma expects a modest financial headwind this year from changes to Medicare prescription drug benefits under the ...
RedHill stock rises on expanded Medicare coverage
Shares of RedHill Biopharma Ltd. (NASDAQ:RDHL) climbed 5% intra-day Tuesday following the announcement that its H. pylori treatment, Talicia, is now covered by Humana (NYSE:HUM)'s Part D Plan. This ...
RedHill Biopharma’s Talicia now covered by Humana’s Part D Plan
RedHill Biopharma (RDHL) announced the coverage of Talicia by Humana’s Part D Plan, providing access to Talicia for H. pylori therapy to more ...